Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Biomed Microdevices. 2012 Apr;14(2):247–257. doi: 10.1007/s10544-011-9602-y

Fig. 8.

Fig. 8

Inhibition of Bcr-Abl in K562 cell lysates by imatinib mesylate. K562 cell lysate was added to serial dilutions (0–100 μM) of imatinib mesylate and incubated in microchannels containing 5% PEG700DA/20% PEG3400 macroporous hydrogel pillars with immobilized GST-Crkl, and detected with anti-phosphotyrosine. Control pillars (No K562) were not exposed to K562 cell extracts or imatinib mesylate. Error bars = SD (n ≥ 6 spots). P < 0.05 between all inhibitor concentrations.